Biblio
Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study. Stem Cell Res Ther. 2024;15(1):24.
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2024.
Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma. Discov Oncol. 2024;15(1):78.
A multi-center retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML. Blood Adv. 2024.
Novel ZFPL1::NUP98 fusion gene identified in an adult acute myeloid leukemia patient. Int J Lab Hematol. 2024.
. CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr vir. Clin Transl Med. 2023;13(10):e1459.
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2023;16(1):13.
Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience. Hematology. 2023;28(1):2212534.
RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia. Leuk Lymphoma. 2023:1-11.
Validation of the imatinib-therapy failure model. Leukemia. 2023.
Clinical characteristics and prognostic analysis of acute myeloid leukemia patients with PTPN11 mutations. Hematology. 2022;27(1):1184-1190.
.